Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Chronic Lymphocytic Leukemia

Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study

Abstract

Alemtuzumab is active in chronic lymphocytic leukaemia (CLL) patients refractory to alkylators and fludarabine. The aim of this study was to determine the efficacy and safety of subcutaneous alemtuzumab at low dose (10 mg three times per week, for 18 weeks) to 49 patients with pre-treated CLL. The overall response rate was 53%, including 27% of complete responses; it was 42% in patients over 70 years, and 54% in the fludarabine-resistant patients. Forty-five percent of the patients with an unfavourable karyotype responded, including 60% of those with the 17p- aberration. After a median follow-up of 25 months, the median overall time to disease progression was 8 months (responders 12 months, non-responders 4 months). The median overall time to alternative treatment was 9 months (responders 17 months, non-responders 6 months) and median overall survival was 30 months. The treatment was well tolerated: grade IV neutropenia was observed in 17%, and cytomegalovirus (CMV) reactivation in 24% of the patients, with no CMV disease. We observed a total of 30 infections (50% during treatment and 50% during the 12-month follow-up), only one-third of which was severe. This study confirms that low-dose subcutaneous alemtuzumab is effective in poor prognosis CLL, and has a particularly favourable toxicity profile.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554–3561.

    Article  CAS  Google Scholar 

  2. Moreno C, Montserrat E . New prognostic markers in chronic lymphocytic leukemia. Blood Rev 2008; 22: 211–219.

    Article  CAS  Google Scholar 

  3. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910–1916.

    Article  Google Scholar 

  4. Faderl S, O'Brien S, Keating MJ . Monoclonal antibody combinations in CLL: evolving strategies. Best Pract Res Clin Haematol 2007; 20: 781–793.

    Google Scholar 

  5. Christian BA, Lin TS . Antibody therapy for chronic lymphocytic leukemia. Semin Hematol 2008; 45: 95–103.

    Article  CAS  Google Scholar 

  6. Lundin J, Kimby E, Björkholm M, Broliden PA, Celsing F, Hjalmar V et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukaemia (B-CLL). Blood 2002; 100: 768–773.

    Article  CAS  Google Scholar 

  7. Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukaemia. J Clin Oncol 2007; 25: 5616–5623.

    Article  CAS  Google Scholar 

  8. Österborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H treatment in chronic lymphocytic leukemia. J Clin Oncol 1997; 15: 1567–1574.

    Article  Google Scholar 

  9. Cortelezzi A, Pasquini MC, Sarina B, Bertani G, Grifoni F, Colombi M et al. A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with hemotherapy-refractory chronic lymphocytic leukemia. Haematologica 2005; 90: 410–412.

    CAS  PubMed  Google Scholar 

  10. Montillo M, Tedeschi A, Miqueleiz S, Veronese S, Cairoli R, Intropido L et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol 2006; 24: 2337–2342.

    Article  CAS  Google Scholar 

  11. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S et al. National cancer institute-sponsored Working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997.

    CAS  Google Scholar 

  12. The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels,, 9th edn. Little, Brown & Co: Boston, MA., 1994, 253–256.

  13. Lozanski G, Heerema NA, Flinn IW, Smith L, Harbison J, Webb J et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004; 103: 3278–3281.

    Article  CAS  Google Scholar 

  14. Gribben JG, Hallek M . Rediscovering alemtuzumab: current and emerging therapeutic roles. Br J Haematol 2009; 144: 818–831.

    Article  CAS  Google Scholar 

  15. Österborg A . Practical considerations for alemtuzumab therapy in B-cell chronic lymphocytic leukaemia (B-CLL). Cutting Edge 2006; 11: 3–6.

    Google Scholar 

  16. Mould DR, Baumann A, Kuhlmann J, Keating MJ, Weitman S, Hillmen P et al. Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol 2007; 64: 278–291.

    Article  CAS  Google Scholar 

  17. Elter T, Molnar I, Kuhlmann J, Hallek M, Wendtner C . Pharmacokinetics of alemtuzumab and the relevance in clinical practice. Leuk Lymphoma 2008; 49: 2256–2262.

    Article  CAS  Google Scholar 

  18. Stilgenbauer S, Winkler D, Buhler A, Zenz T, Groner S, Busch R et al. Subcutaneous alemtuzumab (MabCampath) in fludarabine-refractory CLL (CLL2H trial of the GCLLSG). Blood 2007; 110 (Part 1): 3120.

    Google Scholar 

  19. Wendtner CM, Ritgen M, Schweighofer CD, Fingerle-Rowson G, Campe H, Jager G et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission—experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004; 18: 1093–1101.

    Article  CAS  Google Scholar 

  20. Lin T, Donohue K, Lucas M, Byrd J, Bengtson E, Peterson B et al. Consolidation therapy with subcutaneous (SC) alemtuzumab results in severe infectious toxicity in previously untreated CLL patients who achieve a complete response (CR) after fludarabine and rituximab (FR) induction therapy: interim safety analysis of the CALGB Study 10101. Blood 2007; 110: 755.

    Google Scholar 

  21. Hainsworth JD, Vazquez ER, Spigel DR, Raefsky E, Bearden JD, Saez RA et al. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer 2008; 112: 1288–1295.

    Article  CAS  Google Scholar 

  22. Hale G, Rebello P, Brettman L, Fegan C, Kennedy B, Kimby E et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukaemia following intravenous or subcutaneous routes of administration. Blood 2004; 104: 948–955.

    Article  CAS  Google Scholar 

  23. Karlsson C, Lundin J, Kimby E, Kennedy B, Moreton P, Hillmen P et al. Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia. Br J Haematol 2009; 144 (1): 78–85.

    Article  CAS  Google Scholar 

  24. Alinari L, Lapalombella R, Andritsos L, Baiocchi RA, Lin TS, Byrd JC . Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene 2007; 26: 3644–3653.

    Article  CAS  Google Scholar 

  25. Vermeulen LC, Puffer EB, Hallam M, Sollinger HW, Hoke R, Kolesar JM . Stability of alemtuzumab for low-dose induction and test doses. Am J Transplant 2009; 9: 651–652.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was partially supported by Associazione Italiana Leucemie (AIL), Milan, Italy.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to A Cortelezzi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cortelezzi, A., Pasquini, M., Gardellini, A. et al. Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study. Leukemia 23, 2027–2033 (2009). https://doi.org/10.1038/leu.2009.148

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2009.148

Keywords

This article is cited by

Search

Quick links